Benzoylpaeoniflorin Activates Anti-Inflammatory Mechanisms to Mitigate Sepsis in Cell-Culture and Mouse Sepsis Models

• Published in: International journal of molecular sciences 2022-10, Vol.23 (21), p.13130
• Main Authors: Kim, Chaeyeong, Sim, Hyunchae, Bae, Jong-Sup
• Format: Article
• Language: English
• Subjects: Animal models; benzoylpaeoniflorin; Bioactive compounds; Biological activity; Cecum; Cell culture; CLP; Cyclooxygenase-1; Cyclooxygenase-2; Cytokines; Cytotoxicity; Drug dosages; Endothelial cells; endothelium; Extracellular signal-regulated kinase; FDA approval; Immunomodulation; Infections; Inflammation; Inflammatory diseases; Interleukin 6; Kinases; Lethal dose; lipopolysaccharide; Lipopolysaccharides; Macrophages; Mortality; mRNA; NF-κB protein; Nitric oxide; Nitric-oxide synthase; Peritoneum; Phosphorylation; Polymerase chain reaction; Pretreatment; Protein kinase; Proteins; Sepsis; Serum levels; Survival; Transcription factors; Tumor necrosis factor-α; Umbilical vein
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232113130

Xuebijing injection (XBJI) (comprising of five herbs) is a widely used traditional Chinese medicine for sepsis treatment. However, the bioactive components of XBJI and the mechanisms responsible for its sepsis-mitigating action have not been experimentally determined. One of the main bioactive compounds in XBJI—benzoylpaeoniflorin (BPF)—inhibits the expressions of key mediators of inflammation such as nuclear factor kappa B (NF-κB), cyclooxygenase-1 (COX-1), and COX-2. However, its effects on sepsis have not been determined yet. Therefore, here, we investigated the immunomodulatory effect of BPF on severely inflamed endothelial cells, THP-1 macrophages, peritoneal macrophages, and mice. Human umbilical vein endothelial cells (HUVECs) and THP-1-macrophages were activated using lipopolysaccharide (LPS) after pretreatment with BPF. Subsequently, changes in the expression profiles of pro-inflammatory molecules including inducible nitric oxide synthase (iNOS), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 were determined using quantitative real-time polymerase chain reaction (qPCR) and Western blot analysis. Furthermore, we monitored the phosphorylation of NF-kB and mitogen-activated protein kinases (MAPKs) to determine their activation levels. Using the LPS-induced mouse model of sepsis, we studied the effects of BPF on inflammatory cytokine production, pulmonary histopathology, and survival rates. Finally, we evaluated whether BPF protects against cecal ligation and puncture (CLP)-induced sepsis, as it closely mimics human sepsis. BPF pretreatment inhibited LPS-induced increase in mRNA and protein levels of iNOS, TNF-α, and IL-6 in HUVECs and THP-1-macrophages. It also suppressed LPS-mediated phosphorylation of p65, p38, JNK, and ERK. Mice with LPS-induced-sepsis who were treated with BPF had lower serum levels of IL-6, TNF-α, IL-1β, CXCL1, and CXCL2 than the control mice treated with BPF. Histopathology revealed that BPF treatment alleviated LPS-induced lung damage. In addition, in mice given a lethal dose of LPS, BPF treatment showed a dose-dependent improvement in survival rates. BPF treatment dose-dependently inhibited the LPS-induced IL-6, TNF-α, and CXCL1 production in peritoneal macrophages. BPF treatment also dose-dependently improved the survival rates in mice with CLP-induced sepsis. These results show that BPF alleviates LPS-stimulated septic conditions and protects mice from CLP-induced sepsis. Our research marks BPF as a potential drug in